VistaGen Therapeutics (NASDAQ:VTGN) Cut to “Hold” at Stifel Nicolaus

Stifel Nicolaus cut shares of VistaGen Therapeutics (NASDAQ:VTGN) from a buy rating to a hold rating in a research note released on Wednesday morning, MarketBeat Ratings reports. They currently have $1.00 price objective on the stock.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of VistaGen Therapeutics in a report on Tuesday, October 21st. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, VistaGen Therapeutics currently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Price Performance

NASDAQ VTGN opened at $0.78 on Wednesday. The business has a 50 day moving average price of $4.00 and a 200 day moving average price of $3.27. The company has a market capitalization of $30.72 million, a P/E ratio of -0.41 and a beta of 0.56. VistaGen Therapeutics has a 1-year low of $0.68 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. On average, research analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VTGN. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics in the 1st quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of VistaGen Therapeutics in the third quarter valued at about $39,000. Bank of America Corp DE raised its holdings in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after buying an additional 19,331 shares during the period. Marshall Wace LLP acquired a new position in VistaGen Therapeutics during the 2nd quarter worth approximately $69,000. Finally, Millennium Management LLC purchased a new position in VistaGen Therapeutics in the 3rd quarter worth approximately $73,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.